Multipurpose Prevention Approaches with Antiretroviral-Based Formulations

We compared the preclinical safety and efficacy of tenofovir (TFV) 1% gel with that of MZC gel [containing 50 μM MIV-150, 14 mM Zn(O2CCH3)2(H2O)2, and 3% carrageenan] through a series of in vitro, ex vivo, and in vivo assays. The two gels showed good antiviral therapeutic indexes (50% cytotoxic conc...

Full description

Bibliographic Details
Main Authors: Jean-Pierre, Ninochka, Barnable, Patrick, Kizima, Larisa, Rodríguez, Aixa, Seidor, Samantha, Cooney, Michael L., Clark, Meredith R., Doncel, Gustavo F., Robbiani, Melissa, Zydowsky, Thomas M., Teleshova, Natalia, Fernández-Romero, José A.
Format: Online
Language:English
Published: American Society for Microbiology 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750675/
Description
Summary:We compared the preclinical safety and efficacy of tenofovir (TFV) 1% gel with that of MZC gel [containing 50 μM MIV-150, 14 mM Zn(O2CCH3)2(H2O)2, and 3% carrageenan] through a series of in vitro, ex vivo, and in vivo assays. The two gels showed good antiviral therapeutic indexes (50% cytotoxic concentration/50% effective concentration ratios; range, >25 to 800). MZC showed greater anti-simian-human immunodeficiency virus reverse transcriptase (SHIV-RT) activity than TFV 1% gel in rhesus macaque vaginal explants. MZC protected mice from vaginal herpes simplex virus 2 (HSV-2) challenge (P < 0.0001), but the TFV 1% gel did not.